Search results for: Multi-Indication Medicines
Filter search results
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
…prices and price growth for top-selling medicines. Share this: Download publication In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented…
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
Share this: Download publication Adrian Towse Lotte Steuten An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination…
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
The National Institute for Health and Care Excellence (NICE) makes recommendations for the use of medicines in the National Health Service (NHS) in England based on their clinical and cost-effectiveness…
Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
23 January 2024
…are a sudden onset of abnormal electrical activity in the brain that temporarily affects how it works. The most common ways of treating epilepsy are medicines called anti-seizure medications (ASMs),…
Dr. Seán Byrne
3 September 2024
Dr Seán Byrne is Senior Manager, Legal & Regulatory Affairs for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Seán represents EUCOPE members at relevant European Medicines Agency and EU institutional…
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
…do not employ HTA processes. Health interventions and technologies to be included in the UCS undergo three separate processes: (i) the National List of Essential Medicines (NLEM), (ii) the Universal…
OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’
18 December 2024
…of Representatives. The two draft bills focus on compulsory insurance for medical care and benefits, one in regards to fair and objective prices for medicines, and the other to enable…
Giving Priority to the Severely Ill: Social Preferences and Value Based Assessment
30 January 2014, 12:00am
…to the sickest patients. The paper is intended to inform the proposed changes to NICE’s methods in 2014, potentially replacing the existing system of QALY multipliers for end-of-life patients with…
OHE Annual Lecture: Universal Health Coverage: the Holy Grail?
8 June 2014, 11:00pm
…Head of the Faculty of Public Health and Policy. She has advised many multilateral, bilateral and government agencies; served on the WHO’s 2001 Commission on Macroeconomics and Health chaird by…